Open an account

Elicio Therapeutics

ELTX · NASDAQ

$1.57+$0.02 (+1.29%)TodayMarket closed ·
Prev close $1.55

ELTX analyst rating

BuyConsensus of 6 analysts over the last 12 months. 83% rate it a buy.
  • Strong buy0
  • Buy5
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $13.94 (+787.9% upside)

Low
$8.08
Now
$1.57
High
$24.15

Upgrades and downgrades

The latest rating actions, newest first

ELTX analyst upgrades, downgrades and rating actions
FirmDateActionRating
B. Riley SecuritiesSep 24, 2026MaintainsBuy
HC Wainwright & Co.Aug 18, 2026MaintainsBuy
Ladenburg ThalmannJun 18, 2026InitiatesBuy
Jones TradingJun 16, 2026DowngradeBuy → Hold
HC Wainwright & Co.Jun 15, 2026MaintainsBuy
B. Riley SecuritiesJun 10, 2026InitiatesBuy
HC Wainwright & Co.May 28, 2026MaintainsBuy
Ladenburg ThalmannApr 15, 2026InitiatesBuy
HC Wainwright & Co.Mar 13, 2026MaintainsBuy
Rodman & RenshawMar 10, 2026InitiatesBuy

The case for and against

Updated Oct 16, 2026

Bull case

Elicio Therapeutics is viewed positively because its AMP platform has produced strong, mechanism-consistent clinical signals in mKRAS-positive disease, with ELI-002 7P showing a 100% T cell response rate in Ph1a at the 4.9 mg dose and broad antigen spreading, while the larger AMPLIFY-201 experience in 90 patients showed a 99% immune response rate. The investment case is further strengthened by the Phase 1 biomarker and survival data for ELI-002 2P, where patients above the 9.17x T cell threshold had an 88% lower risk of relapse or death, median RFS not reached beyond 24 months, and median OS of 28.94 months versus a historical benchmark of ~17 months. With a clean safety profile, off-the-shelf manufacturing advantages, cash guided through YE26, and the adjuvant PDAC opportunity receiving incremental validation, the company appears well positioned for durable clinical and commercial upside.

Bear case

Elicio Therapeutics is a high-risk clinical-stage biotech whose value depends heavily on a single asset, ELI-002 7P, despite only a 65% assumed probability of regulatory approval and a 10% discount rate reflecting meaningful uncertainty. The company faces material execution and regulatory risks, including failure to generate convincing Phase 2 efficacy data, potential delays or failure in pivotal development, possible rejection of regulatory submissions, and slower-than-expected uptake even if approved. Financially, the cash runway extends through 4Q26, but near- to medium-term dilution remains a real threat, while the largely pending patent portfolio and MIT-controlled IP add further commercial fragility.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.